Barleria

Barleria: A Comprehensive Encyclopedic Reference

1. Botanical Identity and Taxonomy

Genus and family. Barleria L. is a genus of flowering plants belonging to the family Acanthaceae. Barleria is the third largest genus in the family Acanthaceae, ranking after Justicia and Ruellia, and it is the most species-rich genus in the tribe Barlerieae. The name Barleria was provided by a French botanist and Dominican monk, Jacques Barrelier (1606–1673), who dedicated his spare time to botany.

Species count and growth form. This genus includes approximately 300 species of shrubs and herbs that are distributed in the subtropical and tropical regions of the world. The genus Barleria comprises herbs, shrubs, or more rarely climbers and tree species.

Geographic distribution. The members of this genus have originated from the Far East of Japan, through southern Asia, Arabia, India, Kenya, Tanzania, Angola, Democratic Republic of the Congo, Namibia, Botswana, Mozambique, southern Africa, and Madagascar to as far west as Central America and Mexico. Barleria is predominantly an "Old World genus," with its maximum species diversity being present in east tropical Africa, followed by South Africa. In southern Africa, there are 70 species of Barleria, of which approximately 65% are endemic to the region.

Most medicinally studied species. A few of the highly important and reported species of Barleria include B. prionitis, B. cristata, B. grandiflora, and B. lupulina. Among these, Barleria prionitis L. has attracted the greatest scientific and ethnopharmacological attention and is the subject of the majority of published phytochemical and pharmacological research. Phytochemical studies in Barleria species have revealed the presence of many biologically active compounds in leaves, stems, and roots; however, these studies pertaining to phytochemical investigations are limited only to nine species: B. cristata, B. courtallica, B. coriacea subsp. dinteri, B. lupulina, B. montana, B. noctiflora, B. prionitis, B. strigosa, and B. trispinosa.

2. Focus Species: Barleria prionitis L.

2.1 Botanical Description and Common Names

Barleria prionitis Linn. (Family: Acanthaceae) is a well-known perennial, Ayurvedic herb distributed in tropical Asia, Africa, and Yemen. It is a shrub native to Island and Mainland Southeast Asia, China, the Indian Subcontinent, the Arabian Peninsula, and northeastern Africa. Broadly found in India, it is distributed widely throughout Asia, including Sri Lanka, Malaysia, Philippines, Bangladesh, and Pakistan, along with tropical Africa.

Vajradanti, Peelo Vajradanti, Bajradanti, Katsareya, Kantajati, Kanta sulio, Barleria, and Yellow Hedge Barleria are a few common names of this spiny erect bush. Its Hindi name is Katsareya; English names include Yellow nail-dye plant and Hop headed Barleria; its Kannada name is Gorantige; Bengali name is Kantajati; Gujarati name is Kantasairiyo; Malayalam name is Chemmulli; Marathi name is Kalsunda; Tamil name is Shemmuli; and Telugu name is Mullu goranti.

Its Sanskrit name is Vajradanti, which literally means "one which makes Danta (teeth) as hard as Vajra (diamond)." It is described as an annual prickly herb with yellow flowers, commonly found in the rainy season throughout the country.

2.2 Plant Parts Used and Common Preparations

The whole plant or its specific parts — leaf, stem, root, bark, and flower — have been utilized for treatment of various ailments. Traditionally utilized in the form of decoctions, gargles, and pastes, various parts of the plant — particularly roots and leaves — have shown therapeutic utility. Ayurvedic practitioners use its leaves and bark to make juice, paste, and decoction.

Modern preparations include:

• Topical gels containing standardized B. prionitis bark or leaf extract, used in periodontal applications.
• Mouthwash/rinse preparations based on aqueous or hydroalcoholic extracts of various plant parts.
• Herbal tooth powders, in which B. prionitis is incorporated as one ingredient alongside other Ayurvedic botanicals.
• Alcoholic (methanolic, ethanolic) and aqueous extracts prepared for laboratory pharmacological screening.

Barleria prionitis is one of the vital ingredients of many herbal tooth formulations.

3. Traditional and Historical Use

3.1 Ayurveda (Indian Subcontinent)

In Ayurveda, Barleria prionitis (known as Saireyaka) is mentioned for the treatment of skin diseases, burning urination, fever, localized swelling, goiter, dental caries, and as a blood purifier. It is most commonly used in Ayurveda for dental care, acute-chronic rheumatism, and inflammatory conditions of the joints. The whole plant is used in Ayurveda for dental care; the herb is considered "Vajradanti" as described in ancient Ayurvedic literature. The word stands for "diamond teeth," implying that it strengthens teeth and makes them as hard as diamond. Thus, in some parts of India, its twigs are used in various forms in dental hygiene.

The therapeutic use of leaf, flower, stem, seed, shoot, root, and in certain cases the complete herb of B. prionitis against numerous disorders including cough, fever, jaundice, asthma, severe pain, acne, and cut wound is recognized by Ayurvedic and other conventional medicinal systems.

3.2 Other South Asian and Southeast Asian Traditions

Several species of Acanthaceae have long been valued in traditional medicinal systems such as Ayurveda, Siddha, and Unani. In the Unani system, Vajradanti (B. prionitis) is incorporated into dental powders prepared by reference to the National Formulary of Unani Medicine.

Barleria lupulina Lindl. (Family: Acanthaceae), commonly known as Bishalyakarani or Vishalyakarani, is an introduced species from Mauritius. It is a small shrub distributed in Southeast Asia, used medicinally: its leaf juice is given to stop bleeding when cut, the leaf-paste is used as a poultice to relieve pain, and it is also used as an anti-inflammatory against insect bites, snake bites, and herpes simplex virus.

Barleria cristata (Family: Acanthaceae), commonly known as Philippine violet, is used in different ethnomedical systems for the treatment of a wide range of ailments. Ethnomedical uses of the plant have been observed in lung disorders, inflammatory conditions, toothache, anaemia, snake bite, diabetes, and tuberculosis.

3.3 Specific Traditional Preparations and Their Reported Uses

Across traditions, the whole plant or parts have been utilized for treatment of toothache, catarrhal affections, whooping cough, inflammations, glandular swellings, urinary infection, jaundice, fever, and gastrointestinal disorders, and as a diuretic and tonic.

• The juice of the leaf is used in cataract and fever; the dried bark is used in cough treatment; and the leaves are chewed to relieve toothache.
• The paste of the root is applied to disperse boils and glandular swellings.
• The leaves are boiled with Kattha and used for rinsing the mouth.
• B. prionitis root (Vajradanti) is used locally on skin to expel spines, in acute stages of cysts in blood vessels, in glandular swellings, as a diuretic, and in bronchial asthma.

4. Key Phytochemical Constituents

Barleria is a prickly shrub found to be enriched with a diverse class of secondary metabolites such as anthraquinones, terpenoids, flavonoids, and iridoid glycosides. Phytochemical investigations reveal the presence of diverse secondary metabolites such as alkaloids, flavonoids, saponins, glycosides, tannins, terpenoids, and phenolic compounds.

4.1 Iridoid Glycosides

The iridoid glycosides are among the most pharmacologically significant and chemically characteristic constituents of B. prionitis. From the aerial parts of Barleria prionitis, one new phenylethanoid glycoside, barlerinoside (1), along with six known iridoid glycosides — shanzhiside methyl ester (2), 6-O-trans-p-coumaroyl-8-O-acetylshanzhiside methyl ester (3), barlerin (4), acetylbarlerin (5), 7-methoxydiderroside (6), and lupulinoside (7) — were isolated. Compounds found in the leaves of B. lupulina also include barlerin, acetylbarlerin, and shanzhiside methyl ester.

A wide variety of biological activities have been demonstrated in vitro, in vivo, and in clinical studies by iridoids or iridoid-rich plants. These activities include antiarthritic, anti-inflammatory, antibacterial, antifungal, anticancer, anticoagulant, antioxidant, antiviral, antispasmodic, immunomodulatory, wound-healing, and neuroprotective effects.

4.2 Phenylethanoid Glycosides

Bioactive compounds such as flavonoids, quinones, iridoids, phenylethanoid glycosides, the immunostimulant protein "Sankaranin," and antibiotics have been isolated from Barleria species. Verbascoside (also known as acteoside) is a notable phenylethanoid glycoside isolated from multiple Barleria species. Verbascoside was first isolated from the Mullein plant (Verbascum sinuatum L.) and has potent biological activities including antioxidant, anti-inflammatory, antineoplastic, wound healing, and neuroprotective effects.

4.3 Flavonoids

Phytochemical analysis of B. prionitis shows the presence of sterols, saponins, tannins, and flavonoids. Flavonoids, sterols/triterpenoids, tannins, and phenolics are known bioactive antidiabetic principles. Flavonoids are also known to regenerate damaged beta cells in alloxan-diabetic rats.

4.4 Other Notable Compounds

A wide range of phytochemical constituents including balarenone, pipataline, prionisides, barlerinoside, verbascoside, shanzhiside methyl ester, barlerin, acetylbarlerin, lupulinoside, and scutellarein have been isolated from the different parts of this plant.

The plant has been reported to have tannin, saponin, flavonoid, glycoside, alkaloid, and phenolic compounds present in it. It is also a noteworthy origin of secondary metabolites such as β-sitosterol, lupeol, syringic acid, and vanillic acid.

The aerial part contains balarenone, terpenoid, barlerinoside, saponins, flavonoids, phenolics, tannins, steroids, carbohydrates, phytosterols, acetyl-barlerin, β-sitosterol, iridoids, and lupulinoside.

Two key metabolites — barlerin and verbascoside — are present in all six studied Barleria extracts (B. cristata, B. lupulina, B. prionitis, B. repens, B. siamensis, and B. strigosa), with B. siamensis exhibiting the highest amount of these compounds at 0.43 mg/g (barlerin) and 1.02 mg/g (verbascoside) of dried leaf, respectively.

4.5 Enzyme Inhibitory Compounds

The phenylethanoid glycoside barlerinoside (compound 1) was significantly active in a glutathione S-transferase (GST) inhibition assay with an IC₅₀ value of 12.4 μM but was only weakly active in an acetylcholinesterase (AChE) inhibition assay. The iridoid glycosides (compounds 2–7) also exhibited different levels of GST, AChE inhibitory, and free radical scavenging activities.

5. Mechanisms of Action

The diverse pharmacological activities of Barleria species are attributed to their complex mixture of secondary metabolites. Proposed mechanisms, based on preclinical research, include:

• Antimicrobial action: The possible mechanism of action of Vajradanti as an antibacterial agent could be due to tannins, saponins, phenolic compounds, essential oils, and flavonoids present in it. The antimicrobial potency of Barleria prionitis may be due to the presence of five iridoid glucoside esters, acetyl barlerin, 6,8-di-O-acetyl shanzhiside methyl ester, shanzhiside methyl ester, and verbascoside.
• Antidiabetic action: Flavonoids, sterols/triterpenoids, tannins, and phenolics are known bioactive antidiabetic principles; flavonoids are also known to regenerate the damaged beta cells in alloxan-diabetic rats.
• Antifertility (male) action: Antifertility effects of Barleria appear to be mediated by disturbances in testicular somatic cell functions (Leydig and Sertoli cells), resulting in physio-morphological events of spermatogenesis.
• Immunomodulatory action: Bioactive compounds such as flavonoids, quinones, iridoids, phenylethanoid glycosides, and the immunostimulant protein "Sankaranin" isolated from Barleria species are responsible for its reported biological activities.
• Anticancer / CYP450 modulation: In a 2025 study, B. cristata and B. siamensis demonstrated significant anti-proliferative activity against PC-3 (prostate cancer) cells by inducing DNA damage, enhancing apoptosis, and obstructing the cell cycle.

6. Scientific Evidence by Area of Use

6.1 Oral Health (Dental / Periodontal)

This is the area in which B. prionitis has attracted the most direct human study.

In vitro antimicrobial evidence against oral pathogens: Crude extract of Barleria prionitis possesses good activity against dental caries-causing oral pathogens where modern therapy has failed. The acetone, methanol, and ethanol extracts of Barleria prionitis Linn. bark exhibited antifungal activity against oral pathogenic fungus Saccharomyces cerevisiae and two strains of C. albicans.

Clinical / human study — mouthwash (2016): A study aimed to evaluate the efficacy of Barleria prionitis extract mouthwash in comparison with the gold standard chlorhexidine (CHX) mouthwash on oral health. A total of 30 subjects were randomly divided into two groups — the B. prionitis group and the CHX gluconate mouthwash group. Data were collected at baseline and at 3 days. Results showed that CHX and B. prionitis were statistically equally effective against dental plaque, although the action of CHX was more pronounced. This is a small, short-duration study (n = 30, 3-day follow-up), limiting its conclusions.

Clinical / human study — Vajradanti gel for gingivitis (2017): The study was conducted in the Department of Periodontology, in collaboration with the Department of Oral and Maxillofacial Surgery, Faculty of Dental Sciences, King George's Medical University, Lucknow, India. Simple random sampling was employed to assign participants to two groups, each having 40 participants. In patients of Group I, scaling and root planing was performed, whereas in patients of Group II, scaling and root planing was performed and subjects were advised to apply Vajradanti gel twice daily after brushing. Parameters including gingival index (GI), plaque index (PI), and probing pocket depth (PPD) were recorded at 0, 4, and 12 weeks. Based on the observations and results of this study, it was concluded that scaling and root planing remains the gold standard for the treatment of gingival and periodontal diseases, while the Vajradanti gel can be effectively used as an adjunct to mechanical plaque control in prevention of chronic gingivitis. The beneficial effect of Vajradanti was attributed to its anti-inflammatory properties.

Compound Ayurvedic formulation study: In a randomized clinical trial, a 100 g Ayurvedic powder formulation containing Babul (Acacia nilotica) 60.0% w/w, Vajradanti (Barleria prionitis) 20.0% w/w, and Bakul (Mimusops elengi) 20.0% w/w was compared to 0.2% chlorhexidine for anti-gingivitis effects. Oral prophylaxis was carried out on the same day to bring the plaque score to zero, and the subjects in both groups were given either the Ayurvedic formulation or 0.2% chlorhexidine by a third person; neither the subjects nor the dental examiner were aware of which group the subjects belonged to.

Evidence assessment for oral health: Human evidence exists and is promising but limited by small sample sizes, short follow-up periods, and the use of multicomponent formulations. No large randomized controlled trials (RCTs) have been published.

6.2 Anti-inflammatory and Antiarthritic Activity

Evidence derived from several studies has demonstrated anti-inflammatory and antiarthritic properties of extracts of species belonging to Barleria. However, the evidence for anti-inflammatory effects in humans is absent; all well-characterized studies are in vitro or animal-based. Recent pharmacological studies highlight its antioxidant and anti-inflammatory activities.

6.3 Antidiabetic Activity

Animal study (PMC, 2010): A study was conducted to evaluate the antidiabetic activity of Barleria prionitis Linn. in normal and alloxan-induced diabetic rats, where alcoholic extract of leaf and root of B. prionitis was tested. Albino rats were divided into six groups of six animals each; in three groups, diabetes was induced using alloxan monohydrate (150 mg/kg body weight, i.p.), and all rats were given different treatments consisting of vehicle, alcoholic extract of leaves, and alcoholic extract of roots of B. prionitis Linn. (200 mg/kg) for 14 days. Blood glucose level, glycosylated hemoglobin, liver glycogen, serum insulin, and body weight were estimated before and 2 weeks after administration of drugs.

Evidence assessment for antidiabetic activity: Current evidence is limited to animal and in vitro studies. No human clinical trials have been published on Barleria for diabetes management.

6.4 Antimicrobial Activity

Evidence from multiple studies has demonstrated antibacterial and antifungal properties of extracts of Barleria species. Metabolites such as alkaloids and terpenoids were reported to contain antimicrobial and anticancer properties.

Evidence assessment for antimicrobial activity: All published evidence is in vitro (test tube / cell culture). No human trials have tested Barleria extracts for systemic infectious disease indications.

6.5 Anthelmintic (Antiparasitic) Activity

The whole plant extract of B. prionitis was reported to have anthelmintic activity. An in vitro study showed that aqueous and ethanolic extracts significantly paralyzed Pheretima posthuma worms at lower doses (50, 75, and 100 mg/mL) and caused death over 100 mg/mL dose concentration, compared to the standard drug albendazole.

Evidence assessment for anthelmintic activity: Preliminary in vitro evidence only. No human clinical data are available.

6.6 Hepatoprotective Activity

Evidence derived from several studies has demonstrated hepatoprotective properties of extracts of species belonging to Barleria. Almost every part of this plant has been screened for various pharmacological activities, including hepatoprotective action. All reported studies are preclinical (in vitro or animal model); no human clinical evidence exists.

6.7 Antioxidant Activity

Among phenolics, gallic acid and caffeic acid were found to be the most common and abundant compounds in leaves and stem of B. prionitis. Antioxidant activity has been documented in in vitro assays across multiple Barleria species. Pharmacological studies highlight its antioxidant activity. All antioxidant data are from in vitro assays; no human clinical antioxidant studies have been published.

6.8 Anticancer / Immunomodulatory Activity

A 2025 study in Scientific Reports (Nature) provided a comprehensive analysis of six Barleria leaf extracts — B. cristata, B. lupulina, B. prionitis, B. repens, B. siamensis, and B. strigosa — to elucidate their metabolite composition, toxicity, immunomodulatory functions, and roles in cytochrome P450 (CYP) gene expression. The findings indicate that B. cristata and B. siamensis demonstrated significant anti-proliferative activity against PC-3 (prostate cancer) cells by inducing DNA damage, enhancing apoptosis, and obstructing the cell cycle. These findings are in vitro only; no clinical cancer or immunomodulatory trials have been published.

6.9 Antiviral Activity

From the pharmacological point, the plant has been effectively screened for antiviral activity. B. lupulina is used as an anti-inflammatory against insect bites, snake bites, and herpes simplex virus. These are preclinical or ethnobotanical observations only.

7. Other Medically Studied Barleria Species

7.1 Barleria cristata L. (Philippine violet)

Barleria cristata (Family: Acanthaceae), commonly known as Philippine violet, is used in different ethnomedical systems for the treatment of a wide range of ailments. Plant parts are rich in various phytochemical constituents including triterpenes, phenolic compounds, glycosides, and flavonoids type phenolic compounds. This species confirms potential as an herb for the treatment of a wide range of diseases especially lung disorders and inflammatory conditions. Modern pharmacological studies have validated many ethnobotanical uses of B. cristata, though data regarding mechanism of action and adverse effects of extracts and active compounds are still limited.

The osteogenic potential of Barleria cristata is intrinsically linked to its complex and diverse phytochemical constitution. This arsenal comprises several classes of secondary metabolites, each contributing uniquely to the observed pharmacological effects through synergistic or additive mechanisms. It is critical to emphasize that the current evidence is derived from preclinical studies; the promising outcomes in animal models justify further investigation but do not confirm clinical efficacy.

7.2 Barleria lupulina Lindl.

Barleria lupulina Lindl. (Family: Acanthaceae) is commonly known as Bishalyakarani or Vishalyakarani, an introduced species from Mauritius, and is distributed in Southeast Asia. Its leaf juice is given to stop bleeding when cut; the leaf-paste is used as a poultice to relieve pain; and it is also used as an anti-inflammatory against insect bites and snake bites.

8. Body Systems and Health Areas Associated with Barleria

The flowers, leaves, stems, roots, and seed extracts of plants belonging to this genus are rich in bioactive compounds and have exhibited significant medicinal potential for the treatment of various ailments and infections. Evidence derived from several studies has demonstrated antioxidant, antibacterial, antifungal, anti-inflammatory, anticancer, antidiabetic, antiulcer, hepatoprotective, analgesic, antiamoebic, antihelminthic, antiarthritic, antihypertensive, and antiviral properties.

• Oral / Dental health: Toothache, gingivitis, dental plaque, oral infections.
• Musculoskeletal system: Arthritis, rheumatism, joint inflammation.
• Metabolic system: Diabetes (preclinical).
• Gastrointestinal system: The plant is a diuretic and is being used in the management of urinary infections and renal dropsy.
• Respiratory system: Cough and asthma are among the disorders recognized by Ayurvedic and other conventional medicinal systems.
• Hepatic system: Liver protection (hepatoprotective; preclinical only).
• Reproductive system: Antifertility effects observed in animal studies (see Section 9).
• Immune system: Immunomodulation via Sankaranin protein and other constituents (in vitro).
• Skin / Wound healing: Traditional topical use for boils, swellings, and wounds.

9. Dosage Forms and Reported Study Dosages

Published studies have used various dosage forms and concentrations. The following are directly cited from source documents:

• Antidiabetic animal study: Alcoholic extract of leaves and roots of B. prionitis Linn. at 200 mg/kg body weight for 14 days.
• Antifertility animal study: Oral administration of root extract of Barleria prionitis L. to male rats at 100 mg/rat per day for a period of 60 days.
• Anthelmintic in vitro study: Aqueous and ethanolic extracts were tested at doses of 50, 75, and 100 mg/mL, with lethality achieved over 100 mg/mL concentration compared to standard drug albendazole.
• Gingivitis clinical study (gel): Subjects were advised to apply Vajradanti gel twice daily after brushing, in addition to scaling and root planing, assessed over 12 weeks.
• Oral health clinical study (mouthwash): A total of 30 subjects were randomly divided into two groups and data were collected at baseline and at 3 days.
• Compound Ayurvedic dental powder: A formulation of 100 g contained Vajradanti (Barleria prionitis) at 20.0% w/w.

No standardized therapeutic dosage has been established for any indication in humans. All preclinical dosages reported above are from animal or in vitro studies and cannot be directly extrapolated to humans.

10. Safety Considerations

10.1 Antifertility Effects in Male Animals

This is the most significant and well-characterized safety signal for B. prionitis and is supported by published peer-reviewed data. Oral administration of root extract of Barleria prionitis L. to male rats (100 mg/rat per day) for 60 days did not cause body weight loss but brought about an interference with spermatogenesis; round spermatids were decreased by 73.6% (P≤0.001). The population of preleptotene spermatocytes was decreased by 41.9%; the extract reduced the fertility of male rats by 100%; and the cross-sectional surface area of Sertoli cells and mature Leydig cell numbers were significantly reduced by 36.9%. The total protein and sialic acid contents of the testes, epididymides, seminal vesicle, and prostate were reduced; testicular glycogen contents were also low. Antifertility effects of Barleria appeared to be mediated by disturbances in testicular somatic cells functions (Leydig and Sertoli cells) resulting in physio-morphological events of spermatogenesis. These findings are from animal studies; effects in humans have not been studied, but the finding is a notable preclinical signal requiring attention.

10.2 CYP450 Gene Expression Modulation

A 2025 study analyzed six Barleria leaf extracts to elucidate their roles in cytochrome P450 (CYP) gene expression. CYP450 enzyme modulation has relevance for potential drug-drug interactions; however, specific human pharmacokinetic interaction data are currently lacking. Pharmacokinetics and molecular-level mechanism studies remain untapped areas of research for Barleria.

10.3 General Toxicity Profile

An exhaustive bibliographic review found that this herb possesses a rich phytochemical content and a wide range of pharmacological activities without any toxic effects at the doses studied. However, formal systematic toxicology evaluations, particularly repeat-dose chronic toxicity, genotoxicity, and reproductive toxicity studies in mammals, are limited or absent in the published literature.

10.4 Evidence Gaps and Research Limitations

Traditionally, the genus Barleria has significant medicinal potential; however, there is a scarcity of information on various species that are yet to be evaluated. Having potential therapeutic importance, it is still underutilized. Data regarding many aspects of this plant such as mechanism of action and adverse effects of extracts and active compounds are still limited, which calls for additional studies. No major government health body (NIH, EMA, WHO) has published a formal safety monograph or dietary supplement fact sheet for Barleria as of the date of this article.

References

• Phytochemicals and Biological Activities of Barleria (Acanthaceae) — PMC / Plants, 2022
• Phytochemicals and Biological Activities of Barleria (Acanthaceae) — PubMed
• Chemical constituents of Barleria prionitis and their enzyme inhibitory and free radical scavenging activities — ScienceDirect / Chinese Chemical Letters, 2008
• Barleria prionitis Linn.: A Review of its Traditional Uses, Phytochemistry, Pharmacology and Toxicity — Research Journal of Phytochemistry, 2012
• A study of the antidiabetic activity of Barleria prionitis Linn — PMC / Pharmacognosy Research, 2010
• Antifertility studies of the root extract of Barleria prionitis Linn in male albino rats — ScienceDirect / Journal of Ethnopharmacology, 2000
• Antifertility studies of the root extract of Barleria prionitis Linn — PubMed
• Assessment of Effectiveness of Barleria prionitis on Oral Health — Pharmacognosy Research, 2016
• Evaluation of Topical Application of Vajradanti Gel in Prevention of Gingivitis — Open Journal of Stomatology, 2017
• Anti-Gingivitis Effect of an Ayurvedic Formulation Versus 0.2% Chlorhexidine on Maintenance Phase — Journal of Basic and Clinical Pharmacy
• Genus Barleria L. (Acanthaceae): a review of its taxonomy, cytogenetics, phytochemistry and pharmacological potential — Journal of Pharmacy and Pharmacology, 2022
• Barleria prionitis L.: An Illustrative Traditional, Phytochemical and Pharmacological Review — Bentham Science / Natural Products Journal, 2020
• Barleria prionitis: Journey from Ayurveda to Modern Medicine — Bentham Science
• Barleria cristata: perspective towards phytopharmacological aspects — Journal of Pharmacy and Pharmacology (Wiley), 2018
• Barleria cristata: perspective towards phytopharmacological aspects — PubMed
• Phytochemical Studies on Two Unexplored Endemic Medicinal Plants of India, Barleria terminalis and Calacanthus grandiflorus — PMC, 2022
• Phytochemical Composition and Antibacterial Activity of Barleria albostellata Leaf and Stem Extracts — PMC, 2023
• Barleria extracts containing barlerin and verbascoside boost immunity and regulate CYP450 gene in prostate cancer — Scientific Reports (Nature), 2025
• A Comparative Review on the Topical Bioactive Phytochemicals in Barleria cristata — Biosciences Biotechnology Research Asia, 2026
• Pharmacological Applications of Barleria lupulina Lindl. — ResearchGate
• Vajradanti (Barleria prionitis): A review of its pharmacognosy, phytochemistry and pharmacological properties — Journal of Pharmacognosy and Phytochemistry, 2025
• Typification of Linnaean Barleria (Acanthaceae) binomials based on Indian material — TAXON (Wiley), 2023
• Saireyaka — Barleria prionitis: Uses, Research, Remedies, Side Effects — Easy Ayurveda